<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02025452</url>
  </required_header>
  <id_info>
    <org_study_id>HHS 13-749</org_study_id>
    <nct_id>NCT02025452</nct_id>
  </id_info>
  <brief_title>Novel Diagnostics and Probiotics to Improve Management of Paediatric Acute Gastroenteritis</brief_title>
  <official_title>Rapid Diagnostics and Probiotic Therapy for Paediatric Acute Gastroenteritis - a Randomized, Factorial, Controlled, Placebo-controlled, Pilot Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jeffrey Pernica</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Grand Challenges Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>BioGaia AB</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hamilton Health Sciences Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Many children admitted to hospital in Botswana without bloody diarrhoea are presumed to have
      viral gastroenteritis and so not treated with antibiotics - but they may indeed have a
      treatable cause for their illness. We will conduct a randomized trial to see if rapid testing
      using novel methods to identify potentially treatable causes of diarrhoea leads to improved
      outcomes. We will also be randomizing children to probiotic therapy versus placebo (the
      standard of care) to see if this treatment decreases the duration of diarrhoea. The proposed
      study is a pilot trial, necessary before embarking on a large multi-centre trial.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Height z-score (HAZ) adjusted for initial HAZ</measure>
    <time_frame>60 days post-enrollment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>mortality</measure>
    <time_frame>60 days post-enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>environmental enteropathy score</measure>
    <time_frame>60 days post-enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of diarrhoea</measure>
    <time_frame>estimated average duration ~ 4 days.</time_frame>
    <description>Note that presence of diarrhoea will be checked daily during admission. Total duration of diarrhoea will be verified with the caregiver by telephone 7 days after the participant was discharged home.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight z-score (WAZ) adjusted for initial WAZ</measure>
    <time_frame>60 days after enrolment</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">76</enrollment>
  <condition>Acute Gastroenteritis</condition>
  <arm_group>
    <arm_group_label>Rapid diagnostics and probiotic</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Rapid diagnostics and placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Delayed diagnostics and probiotic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Delayed diagnostics and placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Rapid diagnostic</intervention_name>
    <description>Specimens from rectal mucosa will be obtained using flocked swabs at enrolment. Those in 'rapid diagnostic' groups will have them tested using multiplex PCR the day of enrolment and participants with treatable pathogens will have antimicrobials provided. Those in 'delayed diagnostic' groups will have the swabs batched at tested at the conclusion of the study, being treated as per standard of care.</description>
    <arm_group_label>Rapid diagnostics and probiotic</arm_group_label>
    <arm_group_label>Rapid diagnostics and placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Probiotic</intervention_name>
    <description>Lactobacillus reuteri suspended in vegetable oil, 5 drops/day (1 x 10e8 CFU) x 2 months</description>
    <arm_group_label>Rapid diagnostics and probiotic</arm_group_label>
    <arm_group_label>Delayed diagnostics and probiotic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Identical in appearance to L. reuteri probiotic (same bottle), but simply vegetable oil. Dose is 5 drops/day x 2 months.</description>
    <arm_group_label>Rapid diagnostics and placebo</arm_group_label>
    <arm_group_label>Delayed diagnostics and placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  acute non-bloody gastroenteritis

        Exclusion Criteria:

          -  diarrhoea &gt; 14 days

          -  sepsis, pneumonia, UTI, meningitis requiring empiric antibiotic therapy

          -  malignancy, IBD

          -  known link to another patient with diarrhoea of defined aetiology

          -  transferred in already on antimicrobials

          -  live outside study area

          -  children with severe acute malnutrition will be eligible for diagnostic arm but not
             probiotic arm
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Months</minimum_age>
    <maximum_age>60 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey Pernica, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>McMaster University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Princess Marina Hospital</name>
      <address>
        <city>Gaborone</city>
        <country>Botswana</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scottish Livingstone Hospital</name>
      <address>
        <city>Molepolole</city>
        <country>Botswana</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bamalete Lutheran Hospital</name>
      <address>
        <city>Ramotswa</city>
        <country>Botswana</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Botswana</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 28, 2013</study_first_submitted>
  <study_first_submitted_qc>December 31, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 1, 2014</study_first_posted>
  <last_update_submitted>March 23, 2017</last_update_submitted>
  <last_update_submitted_qc>March 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hamilton Health Sciences Corporation</investigator_affiliation>
    <investigator_full_name>Jeffrey Pernica</investigator_full_name>
    <investigator_title>Head, Division of Pediatric Infectious Disease</investigator_title>
  </responsible_party>
  <keyword>diarrhoea</keyword>
  <keyword>gastroenteritis</keyword>
  <keyword>rapid diagnostics</keyword>
  <keyword>probiotics</keyword>
  <keyword>sub-Saharan Africa</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroenteritis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

